Clinical trial
CD123-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Myelocytic Leukemia（AML）
NCT03556982 is registered in ClinicalTrials.gov with The Affiliated Hospital of the Chinese Academy of Military Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CD123-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Myelocytic Leukemia（AML）
- Lead sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- March 1, 2018
- Completion date
- March 1, 2020
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.